INVITED SPEAKER

TARGETING NON-CODING RNAS WITH SYNTHETIC SMALL MOLECULES FOR INNOVATIVE THERAPEUTIC APPLICATIONS

D.D. VO [1], C. MARTIN [1], C. MAUCORT [1], C. STAEDEL [2], F. DARFEUILLE [2], A. DI GIORGIO [1], M. DUCA [3]

[1]Institut de chimie de Nice - Nice (France), [2]Laboratoire ARNA - Bordeaux (France), [3]Institut de Chimie de Nice- Université Cote d'Azur/CNRS - Nice (France)

RNA is one of the most intriguing and promising biological targets for the discovery of innovative drugs in a large number of pathologies and various biologically relevant RNAs that could serve as drug targets have already been identified. Among the most important ones, it is worth to mention prokaryotic ribosomal RNA which is the target of a number of currently employed antibiotics, viral RNAs such as TAR, RRE and DIS RNA of HIV-1 or oncogenic microRNAs that are tightly involved in the development and progression of various cancers. However, difficulties in the rational design of strong and specific small-molecule ligands renders this kind of molecules relatively rare.

In this presentation, we will show our recent results about the structure-based design of new RNA ligands targeting in particular viral and oncogenic RNAs that led us to the identification of new compounds bearing a promising biological activity but also to a better understanding of the formed interaction toward the design of optimized compounds. In parallel to the design of bioactive compounds, we also perform the screening of chemical library thus increasing the available chemical tools for the development of efficient and specific RNA binders for a wide number of therapeutic applications.

(1) Maucort, C., Vo, D.D., Aouad, S., Charrat, C., Azoulay, S., Di Giorgio, A., Duca, M. Design and implementation of synthetic RNA binders for the inhibition of miR-21 biogenesis. ACS Med. Chem. Lett. 2021, 12, 899; Joly JP, Gaysinski M, Zara L, Duca M*, Benhida R.* Functionalized C-nucleosides as remarkable RNA binders: targeting of prokaryotic ribosomal A-site RNA. Chem. Commun. 2019 27, 10432; Vo, D.D., Becquart, C., Tran, T.P.A., Staedel, C., Darfeuille, F., Di Giorgio, A., Duca, M. Org. Biomol. Chem. 2018 16, 6262; Vo, D.D., Tran, T.P.A. Staedel, C., Benhida, R., Darfeuille, F., Di Giorgio, A., Duca, M. Chem. Eur. J. 2016 22, 5350.

(2) Martin C., De Piccoli S., Gaysinski M., Becquart C., Azoulay S., Di Giorgio A., Duca M. Unveiling RNA Binding Properties of Verapamil and Preparation of New Derivatives as Inhibitors of HIV-1 Tat-TAR Interaction. ChemPlusChem 2020 85, 207; Staedel, C., Tran, T.P.A., Giraud, J., Darfeuille, F., Di Giorgio, A., Tourasse, N.J., Salin, F., Uriac, P., Duca, M. Sci. Rep. 2018 8, 1667; Tran T.P.A., Vo D.D., Di Giorgio A., Duca M. Bioorg. Med. Chem. 2015 23, 5344.